Long-term remission of Crohn's disease treated with thalidomide: A seminal case report
- 70 Downloads
A 31-year-old female with severe Crohn's disease for 15 years who had been treated with corticosteroids and 6-mercaptopurine, was treated with thalidomide initially for erythema nodosum. While on thalidomide all symptoms of Crohn's disease disappeared and she was able to discontinue all other drugs. At this writing she has been on thalidomide as sole therapy for over 4 years with the exception of a 5-week hiatus, during which time her symptoms recurred, but again disappeared after resumption of thalidomide therapy. This case suggests that thalidomide may be a useful therapy for Crohn's disease and provides impetus for a clinical trial of thalidomide for Crohn's disease.
Unable to display preview. Download preview PDF.
- 4.Fine HA, Loeffler JS, Kyritsis A et al. A phase II trial of the anti-angiogenic agent, thalidomide in patients with recurrent high-grade gliomas. Proc Am Soc Clin Oncol 1997; 16 (Abstr #1372).Google Scholar
- 5.Singal S, Mehta J, Eddlemon P et al. Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM). Blood 1998; 92: 318a (Abstr 1306, Suppl 1).Google Scholar
- 7.Hamuryundan V, Mat C, Saip S et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 443–50.Google Scholar
- 14.Jacobson JM, Greenspan JS, Spritzler J et al. For the National Institute of Allergy and Infection Diseases AIDS Clinical Trial Group. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency viral infection. N Engl J Med 1997; 336: 1487–93.PubMedCrossRefGoogle Scholar
- 19.Folkan J, Brem H. Angiogenesis and inflammation. In: Gallin JL, Goldstein IM, Snyderman R (eds) Inflammation: Basic Principles and Clinical Correlates. Second edition. New York: Raven Press 1992; Chapter 40, 821–39.Google Scholar
- 21.Bousvaros A, Zurakowski D, Fishman SJ et al. Serum basic fibroblast growth factor in pediatric Crohn's disease: Implications for wound healing. Dig Dis Sci 1997; 42: 3783–6.Google Scholar
- 23.Taylor CT, Lisco SJ, Fishman SJ, Colgan SP. T84 intestinal epithelial cells express a functional VEGF receptor: Potential role in the regulation of ion transport. Gastroenterology 1997; 112: A1194.Google Scholar
- 24.Spalinger JH, Patriquin H, Miron M-C et al. Doppler sonography in Crohn's disease: Intestinal vessel density reflects disease activity. 1999; in press.Google Scholar
- 27.Murch SH, Braegger CP, Walter-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1994; 34: 1705–9.Google Scholar